August 2024
Biogen Lifts Outlook as Leqembi Sales Accelerate in Q2
Biogen, Leqembi, Q2 earnings, Alzheimer’s drug, cost cuts, profit outlook
Healx Initiates Phase II Trial for AI-Discovered Rare Disease Candidate with $47M Funding
Healx, AI-discovered, rare disease, neurofibromatosis Type 1, Phase II trial, $47M funding
Sanofi Invests €1.3 Billion in Next-Generation Insulin Facility in Frankfurt
Sanofi, insulin facility, Frankfurt, diabetes treatment, next-generation insulin, €1.3 billion investment
Gene Therapy Pioneer Jim Wilson Departs UPenn to Launch Two New Biotech Companies
Jim Wilson, UPenn, gene therapy, biotech companies, GEMMA Biotherapeutics, Franklin Biolabs
Novartis Sues FDA Over Approval of Entresto Generic After Petition Rejection
Novartis, FDA, Entresto, generic drug, lawsuit, patent exclusivity, heart failure medication
Roche Accelerates Obesity Drug Development and Explores M&A Opportunities
Roche, obesity drugs, M&A, pharmaceuticals, drug development
Sanofi Invests €1.3 Billion in New Insulin Manufacturing Plant in Frankfurt
Sanofi, insulin manufacturing, Frankfurt, €1.3 billion, BioCampus, digital solutions, diabetes patients, European supply chain
Pfizer Considers Facility Sale Amid GSK’s Administrative Breach in South Korea
Pfizer, facility sale, GSK, administrative breach, South Korea, pharmaceutical industry
Teladoc Posts $838M Loss in Q2, Announces Strategic Pivot for BetterHelp
Teladoc, BetterHelp, Q2 loss, strategic pivot, telehealth, virtual healthcare
Biogen Retains Biosimilars as Eisai-Partnered Leqembi Advances Amid Business Shift
Biogen, biosimilars, Leqembi, Eisai, Alzheimer’s disease, business pivot, pharmaceuticals, biotechnology